Article Type
Changed
Fri, 06/11/2021 - 10:21
Display Headline
The Horizon for Treating Cutaneous Vascular Lesions
This article provides a brief introduction to these entities, including current treatment options and limitations of these therapies.

Amit M. Patel, MD* Elizabeth L. Chou, BS, Laura Findeiss, MD, and Kristen M. Kelly, MD

Dermatologists encounter a wide range of cutaneous vascular lesions, including infantile hemangiomas, port-wine stain birthmarks, arteriovenous malformations, venous malformations, Kaposi sarcomas, angiosarcomas, and angiofibromas. Current treatment modalities to reduce these lesions include topical and/or intralesional steroids, laser therapy, surgical resection, and endovascular therapy. However, each method has limitations owing to recurrence, comorbidities, toxicity, or lesion location. Photodynamic therapy, antiangiogenic therapy, and evolving methods of sclerotherapy are promising areas of development that may mitigate limitations of current treatments and offer exciting options for patients and their physicians.

*For a PDF of the full article, click on the link to the left of this introduction.

Article PDF
Author and Disclosure Information

Publications
Topics
Legacy Keywords
vascular malformations, infantile hemangiomas, port-wine stain, Kaposi sarcoma, angiosarcomas, angiofibromas, photodynamic therapy, angiogenesis inhibitors, sclerotherapy
Sections
Author and Disclosure Information

Author and Disclosure Information

Article PDF
Article PDF
This article provides a brief introduction to these entities, including current treatment options and limitations of these therapies.
This article provides a brief introduction to these entities, including current treatment options and limitations of these therapies.

Amit M. Patel, MD* Elizabeth L. Chou, BS, Laura Findeiss, MD, and Kristen M. Kelly, MD

Dermatologists encounter a wide range of cutaneous vascular lesions, including infantile hemangiomas, port-wine stain birthmarks, arteriovenous malformations, venous malformations, Kaposi sarcomas, angiosarcomas, and angiofibromas. Current treatment modalities to reduce these lesions include topical and/or intralesional steroids, laser therapy, surgical resection, and endovascular therapy. However, each method has limitations owing to recurrence, comorbidities, toxicity, or lesion location. Photodynamic therapy, antiangiogenic therapy, and evolving methods of sclerotherapy are promising areas of development that may mitigate limitations of current treatments and offer exciting options for patients and their physicians.

*For a PDF of the full article, click on the link to the left of this introduction.

Amit M. Patel, MD* Elizabeth L. Chou, BS, Laura Findeiss, MD, and Kristen M. Kelly, MD

Dermatologists encounter a wide range of cutaneous vascular lesions, including infantile hemangiomas, port-wine stain birthmarks, arteriovenous malformations, venous malformations, Kaposi sarcomas, angiosarcomas, and angiofibromas. Current treatment modalities to reduce these lesions include topical and/or intralesional steroids, laser therapy, surgical resection, and endovascular therapy. However, each method has limitations owing to recurrence, comorbidities, toxicity, or lesion location. Photodynamic therapy, antiangiogenic therapy, and evolving methods of sclerotherapy are promising areas of development that may mitigate limitations of current treatments and offer exciting options for patients and their physicians.

*For a PDF of the full article, click on the link to the left of this introduction.

Publications
Publications
Topics
Article Type
Display Headline
The Horizon for Treating Cutaneous Vascular Lesions
Display Headline
The Horizon for Treating Cutaneous Vascular Lesions
Legacy Keywords
vascular malformations, infantile hemangiomas, port-wine stain, Kaposi sarcoma, angiosarcomas, angiofibromas, photodynamic therapy, angiogenesis inhibitors, sclerotherapy
Legacy Keywords
vascular malformations, infantile hemangiomas, port-wine stain, Kaposi sarcoma, angiosarcomas, angiofibromas, photodynamic therapy, angiogenesis inhibitors, sclerotherapy
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media